Hyperbaric oxygen as an adjuvant treatment for patients with COVID-19 severe hypoxaemia: a randomised controlled trial.

Background: Hyperbaric oxygen (HBO) therapy has been proposed to treat hypoxaemia and reduce inflammation in COVID-19. Our objective was to analyse safety and efficacy of HBO in treatment of hypoxaemia in patients with COVID-19 and evaluate time to hypoxaemia correction.

Methods: This was a multicentre, open-label randomised controlled trial conducted in Buenos Aires, Argentina, between July and November 2020.

Precision Medicine in the Renin-Angiotensin System: Therapeutic Targets and Biological Variability.

Pathologies linked to the renin-angiotensin system are frequent, and the drugs used in them are numerous and show great variability in therapeutic effects and adverse reactions. Genetic variants have been detected in the angiotensinogen gene (6), angiotensin-converting enzyme (9), angiotensinconverting enzyme 2 (1), and angiotensin receptor Type 1 (4) among others. However, the large number of studies that have analyzed each of them makes it complex and almost impossible to consider all the existing information.